KRAS and neoplasm: In summary, these data demonstrate that the inhibition in cellular growth in vitro, observed upon treatment with pan-KRAS “OFF” inhibitors, leads to suppression of tumor growth in vivo in preclinical models of KRAS WT–amplified cancers.